Phase I results of inhaled 5-azacytidine for the treatment of advanced non-small cell lung cancer Sep. 9, 2019
PRC2 inhibitors patented by Shanghai Institute of Materia Medica, Suzhou Suplead Life Sciences Sep. 9, 2019
RSS